Abdominal unicentric Castleman’s disease: a case report

Samir Bradai, Amal Khsiba, Abdelwaheb Nakhli, Moufida Mahmoudi, Asma Ben Mohamed, Abir Chaabane, Emna Chelbi, Medhioub Mona, Lamine Hamzaoui, Mousadek Azouz

Corresponding author: Samir Bradai, Gastroenterology Department, Mohamed Tahar Maamouri Hospital, Nabeul, Tunisia. bradaisamir78@gmail.com

Received: 13 Mar 2021 - Accepted: 28 Mar 2021 - Published: 08 Apr 2021

Keywords: Castleman’s disease, abdominal localization, surgery, case report

Copyright: Samir Bradai et al. Pan African Medical Journal (ISSN: 1937-8688). This is an Open Access article distributed under the terms of the Creative Commons Attribution International 4.0 License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Cite this article: Samir Bradai et al. Abdominal unicentric Castleman’s disease: a case report. Pan African Medical Journal. 2021;38(339). 10.11604/pamj.2021.38.339.28859

Available online at: https://www.panafrican-med-journal.com/content/article/38/339/full

Abdominal unicentric Castleman's disease: a case report

Samir Bradai1*, Amal Khsiba1, Abdelwaheb Nakhli1, Moufida Mahmoudi1, Asma Ben Mohamed1, Abir Chaabane2, Emna Chelbi2, Medhioub Mona1, Lamine Hamzaoui1, Mousadek Azouz1

1Gastroenterology Department, Mohamed Tahar Maamouri Hospital, Nabeul, Tunisia,
2Histopathology Department, Mohamed Tahar Maamouri Hospital, Nabeul, Tunisia

*Corresponding author
Samir Bradai, Gastroenterology Department, Mohamed Tahar Maamouri Hospital, Nabeul, Tunisia
Abstract

Castleman’s disease is a rare disease characterized by benign lymphoepithelial proliferation. There are two forms: unicentric and multicentric Castleman’s disease. Mediastinal location is the most frequent. Intra-abdominal Castleman’s disease is a rare presentation. We report a case of 65-year-old female who presented with epigastric pain. Investigations revealed a retroperitoneal mass which was surgically resected. Histopathological examination showed hyaline-vascular type Castleman’s disease. In conclusion, Castelman’s disease is a diagnostic challenge and it must be included in the differential diagnosis of retroperitoneal tumors.

Introduction

Castleman’s disease (CD) was first described by Benjamin Castelman in 1954 [1]. It is characterized by an angiofollicular lymph node hyperplasia. Two forms are observed: unicentric (UCD) and multicentric (MCD). Unicentric is the most common one (90%) and is generally asymptomatic [2]. Mediastinum is the most common site. The abdomen is rarely affected by this pathology [3]. We present a case of a female patient with an abdominal pseudotumor Castleman’s Disease for which she underwent surgery.

Patient and observation

A 62-year-old female presented with intermittent epigastric pain of one month duration. Her past medical history was significant for type II diabetes and hypercholesterolaemia. She had no family history of malignancy. Physical examination was normal. She had no cervical, axillary or inguinal lymphadenopathy. Routine blood parameters were normal. Upper gastrointestinal endoscopy was normal. Ultrasound imaging showed a homogeneously hypoechoic epigastric mass. Computerized tomography (CT) of the abdomen revealed a mass measuring 3 cm arising between the first portion of duodenum and the pancreas.

Since the mass was small and retroperitoneal, we decided to proceed to mass excision. Intraoperatively, there was a well-encapsulated soft-tissue mass measuring 3.5 x 2.5 x 1.5 cm, firm in consistency and deriving blood supply from multiple sources (Figure 1). Mass was excised in toto. The patient recovered without complications and was discharged within two days. Microscopic examination showed lymphoid parenchyma composed of multiple lymphoid follicles of variable size with characteristic “onion skin” layering of lymphocytes in the mantle zone. In interfollicular sectors, multiple hyaline vascular structures were noticed, giving “lollipop” appearance (Figure 2). Immunohistochemical study revealed that tumor cells were positive for CD20+ mainly in the follicular regions (Figure 3). B-cell lymphoma 2 (Bcl-2) and human herpesvirus 8 (HHV-8) antibody were negative. Human immunodeficiency virus test (HIV) was also negative. The patient is currently doing well, nine months after the surgery.

Discussion

Castleman’s disease is rare with an incidence of 25 per million patient-years [1]. It is characterized by an angiofollicular lymph node hyperplasia. There are two presentations of CD according to the number of lymph nodes involved: unicentric and multicentric types. Unicentric Castleman’s disease is a localized disease affecting a single enlarged lymph node or a group of adjacent nodes. It is the most frequent type of CD (90% of cases). This variant is usually asymptomatic or paucisymptomatic [1,2]. Multicentric affects multiple lymph node areas. In this form, patients mostly present with fever, night sweats, weight loss, generalized lymphadenopathy and hepatosplenomegaly [1,4]. Computerized tomography scan shows a homogeneous or heterogeneous mass of soft-tissue density with rim enhancement and slow washout [5]. In unicentric Castleman’s disease, mediastinum is the most common site (70%) [3]. The abdomen is rarely affected and only few cases have been reported [3]. The retroperitoneal location, as in our case, is very
rare and represents only 7% of cases [6]. Preoperative needle biopsy or fine needle aspiration is not recommended because mostly the amount of tissue is not sufficient to confirm the diagnosis. Besides, there is a possibility of spreading tumor cells and a risk of severe bleeding. Hence, the diagnosis is usually based on pathology after surgical resection [7]. Histologically, CD can be categorized into either hyaline-vascular type, plasma cell type or mixed type. Hyaline-vascular type consists of proliferation of small lymph follicles with hyalinization of its wall while Plasma cell type contains polyclonal plasma cells with a less marked hyalinization and vascularization [1,3]. Usually, UCD has a hyaline-vascular type morphology while MCD has plasma cell type or mixed type [1].

The etiology of this pathology is unknown. Chronic inflammation, immunodeficiency, autoimmunity, tuberculosis, toxoplasmosis and Epstein Barr virus have been incriminated [3]. Some multicentric forms are associated with HSSV-8 or HIV infections [8]. The role of Interleukin 6 (IL6) has been reported in the genesis of MC disease [7]. Surgical resection is the gold standard treatment for UCD [7]. In our case, the lesion was totally removed. For unresectable cases, aggressive surgical treatment is not recommended as this may increase the rates of morbidity and mortality. Mass reduction with neoadjuvant rituximab and radiotherapy can allow complete surgical resection with a lower morbidity [9]. If the resection is successful, prognosis is excellent [7]. Multicentric Castelman’s disease is more aggressive and has a poor prognosis [1]. Given that the disease is rare, there are no firm recommendations. Many agents have been tried, such as immunotherapy with monoclonal antibodies directed at IL-6 (siltuximab), antiviral agents when MCD is associated with HSSV-8 or HIV infections, and chemotherapeutic agents (doxorubicin, vincristine, cyclophosphamide, melphalan, and chlorambucil) [7]. MCD may progress to lymphoma, therefore a regular surveillance is mandatory [10].

Conclusion

Unicentric Castelman’s disease is a diagnostic challenge and it must be included in the differential diagnosis of retroperitoneal tumors. Preoperative diagnosis is difficult due to a lack of specific radiologic markers and the poor performance of biopsy. Complete resection is the gold standard treatment for UCD. Further studies are needed to establish recommendation for the management of MCD.

Competing interests

The authors declare no competing interests.

Authors’ contributions

All the authors have contributed to the management of the patient and the write up of the manuscript. They have read and agreed to the final version of the manuscript.

Figures

Figure 1: intraoperative aspect; white arrow: Castelman tumor; yellow arrow: pancreatic head; green arrow: duodenum
Figure 2: histological examination; Castleman’s disease of hyaline vascular type
Figure 3: immunohistochemical staining positive for CD20+

References

1. Wu D, Lim MS, Jaffe ES. Pathology of Castleman disease. Hematol Oncol Clin North Am. 2018;32(1): 37-52. Google Scholar
2. Ozsoy M, Ozsoy Z, Sahin S, Arikant Y. Rare forms of Castleman disease mimicking malignancy: mesenteric and pancreatic involvement. Cureus. 2018 Mar;10(3): e2310. PubMed | Google Scholar
3. Greco LG, Tedeschi M, Stasolla S, Gentile A, Gentile A, Piscitelli D. Abdominal nodal localization of Castleman’s disease: report of a case. Int J Surg. 2010;8(8): 620-2. PubMed | Google Scholar

4. Liu AY, Nabel CS, Finkelman BS, Ruth JR, Kurzrock R, van Rhee F et al. Idiopathic multicentric Castleman’s disease: a systematic literature review. Lancet Haematol. 2016;3(4): e163-175. PubMed | Google Scholar

5. Gopi P, Potty VS, Kaurav RS, Govindan K. Unicentric Castleman’s disease as a localized retroperitoneal mass: a case report and review of literature. Int J Appl Basic Med Res. 2018;8(4): 259-62. PubMed | Google Scholar

6. Aygun C, Tekin MI, Demirhan B, Peskircioğlu CL, Agildere M, Ozkardes H. A case of incidentally detected Castleman’s disease with retroperitoneal paravertebral localization. Int J Urol. 2000;7(1): 22-5. PubMed | Google Scholar

7. Imen BI, Zenaidi H, Abdelwahed Y, Sabeur R, Ayoub Z. Management of isolated retroperitoneal Castelman’s disease: a case report. Int J Surg Case Rep. 2020;70: 24-7. PubMed | Google Scholar

8. Yu L, Tu M, Cortes J, Xu-Monette ZY, Miranda RN, Zhang J et al. Clinical and pathological characteristics of HIV- and HHV-8-negative Castleman disease. Blood. 2017;129(12): 1658-68. PubMed | Google Scholar

9. Baek HJ, Kook H, Han DK, Shin M-G, Kim HS, Hwang TJ. Unicentric Castleman disease relapsed after rituximab-CHOP chemotherapy or radiation therapy in an adolescent. J Pediatr Hematol Oncol. 2012;34(5): e206-208. PubMed | Google Scholar

10. El-Osta HE, Kurzrock R. Castleman’s disease: from basic mechanisms to molecular therapeutics. Oncologist. 2011;16(4): 497-511. PubMed | Google Scholar

Figure 1: intraoperative aspect; white arrow: Castleman tumor; yellow arrow: pancreatic head; green arrow: duodenum
Figure 2: histological examination; Castleman’s disease of hyaline vascular type

Figure 3: immunohistochemical staining positive for CD20+